• Pier Paolo Sainaghi, Federica Alciato, Stefania Carnieletto, Luigi Castello, Luca Bergamasco, Daniele Sola, Angelo Sante Bongo, Eugenio Inglese, Riccardo Polosa, and Gian Carlo Avanzi.
• Internal Medicine, Department of Clinical and Experimental Medicine, University of Eastern Piedmont A. Avogadro, Novara, Italy.
• Respir Med. 2009 Apr 1; 103 (4): 589-94.

BackgroundGas6 protein is involved in pulmonary embolism (PE) and acute inflammation in animal models.MethodsWe enrolled 82 consecutive patients with acute dyspnea and suspected PE (Geneva score with high (HCP) or low/intermediate clinical probability (LICP)+D-dimer >or=0.5microg/mL) and 29 age-matched healthy volunteers. According to clinical and instrumental evaluations the following diagnoses were obtained: heart failure (HF), pulmonary or systemic infection (I), PE, or no illness (N). Twenty-two patients were excluded due to oral anticoagulation (9), lack of CT angiography or pulmonary scintigraphy (6), plasma creatinine >or=3mg/dL (3), and pulmonary cancer (4). Plasma Gas6 was measured with a validated enzyme-linked immunoassay. Non-parametric tests and accuracy measures were calculated.ResultsOut of 60 patients included, 8 were N, 12 HF, 11 I and 29 PE. Gas6 median value in the N group (20.4ng/mL, interquartile range 17.6-21.6) matched that of healthy volunteers, 19.1 (17.2-21.4). Median Gas6 values in HF, 26.4 (21.6-33.3) and I groups, 34.1 (30.0-38.7), were significantly higher than those in PE 18.2 (16.3-23.3) or N (Kruskal-Wallis test pConclusionsThe data link Gas6 protein to infection/inflammation, but not to PE, in humans. Gas6 assay was useful in PE diagnosis, improving D-dimer accuracy particularly in LICP patients, and limiting false positives.

33 keywords...

hide…